Therapeutic Antibodies – News and Features

Explore cutting-edge technologies and workflows advancing downstream processing in biopharma, driving purification efficiency and innovation in new therapies.

Learn how AI and machine learning enhance antibody discovery – from structure prediction to binding optimization – with robust data and lab informatics.

Researchers developed a nasal antibody that blocks mugwort pollen, a major hay fever trigger in Europe and Central Asia. Delivered intranasally, it reduced allergic symptoms and inflammation in mice without systemic side effects.

A team of researchers has identified a potential new strategy to prevent, or even reverse, immune checkpoint inhibitor–induced type 1 diabetes.

This article explores the relationship between the immune system and cancer and outlines therapeutic strategies that leverage a patient’s immune system to treat cancer.

A CU Anschutz study also identified the presence of a bacterium that causes gum disease in joint tissue, meaning it may play a role in the development of rheumatoid arthritis.

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform personalized cancer care.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1.

Researchers have developed new CAR-T cells to target malignant tumors. Their method targeted a protein found in high amounts on many types of cancer cells (Eva1) and successfully eliminated tumors in lab mice.

A new Phase 2 trial suggests that using an electric field device placed on the scalp, along with immunotherapy and chemotherapy may help patients with glioblastoma live longer – particularly those with large, inoperable tumors.